The U.S. FDA has approved Amgen’s targeted immunotherapy for adults with extensive-stage small cell lung cancer. | Amgen

Today, we are proud to announce the U.S. FDA approval of the first and only biologic treatment for #severeasthma without a phenotype or biomarker limitation within its approved label. This marks an important milestone in asthma research 🔬, bringing us one step closer to helping people try to live a life less defined by their disease. https://www.amgen.com/newsroom/press-releases/2021/12/fda-approves-tezspire-tezepelumabekko-in-the-us-for-severe-asthma | Amgen